FKS mutant Candida glabrata: Risk factors and outcomes in patients with candidemia

Clinical Infectious Diseases

Volumn 59, Issue 6, 2014, Pages 819-825

  Beyda, Nicholas D ^a   John, Julie ^a   Kilic, Abdullah ^a   Alam, Mohammad J ^a   Lasco, Todd M ^b   Garey, Kevin W ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b CHI ST LUKE S HEALTH BAYLOR ST LUKE S MEDICAL CENTER   (United States)

Author keywords

Antifungal resistance; Candida glabrata; Echinocandins; Micafungin; Systemic candidiasis

Indexed keywords

CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; ANTIFUNGAL AGENT; FUNGAL PROTEIN; LIPOPEPTIDE;

ADULT; AGED; ARTICLE; BLOODSTREAM INFECTION; CANDIDA GLABRATA; CANDIDEMIA; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; EXPOSURE; FEMALE; FUNGUS ISOLATION; GENE MUTATION; HUMAN; ILEUS; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; RISK FACTOR; SMALL INTESTINE OBSTRUCTION; STOMACH OBSTRUCTION; TERTIARY CARE CENTER; TREATMENT RESPONSE; ANTIFUNGAL RESISTANCE; CANDIDIASIS; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MUTATION; PROGNOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDEMIA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; FUNGAL PROTEINS; HUMANS; LIPOPEPTIDES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; RISK FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906936191     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu407     Document Type: Article

References (16)

1. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care 2010; 16:445-52.
2. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother 2011; 55:561-6.
3. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol 2011; 49:396-9.
4. Beyda ND, Lewis RE, Garey KW. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother 2012; 46:1086-96.
5. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3- -D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother 2009; 53:3690-9.
6. Arendrup MC, Perlin DS, Jensen RH, Howard SJ, Goodwin J, Hope W. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob Agents Chemother 2012; 56:2435-42.
7. Beyda ND, Chuang SH, Alam MJ, et al. Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother 2012; 68:438-43.
8. Shah DN, Yau R, Weston J, et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother 2011; 66:2146-51.
9. Zimbeck AJ, Iqbal N, Ahlquist AM, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother 2010; 54:5042-7.
10. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47:674-83.
11. Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013; 56:1724-32.
12. Cleveland AA, Farley MM, Harrison LH, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012; 55:1352-61.
13. Shields RK, Nguyen MH, Press EG, et al. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother 2012; 56:4862-9.
14. Perlin DS. Current perspectives on echinocandin class drugs. Future Microbiol 2011; 6:441-57.
15. Pfaller MA, Chaturvedi V, Diekema DJ, et al. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Diagn Microbiol Infect Dis 2012; 73:365-8.
16. Espinel-Ingroff A, Arendrup MC, Pfaller MA, et al. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrobial Agents Chemother 2013; 57:5836-42.